Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Zydus announces IND clearance of a novel Anti-PCSK9 candidate

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity

Apollo Hospitals celebrates its leadership position as the largest Cardiac care programme in India

Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries

Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData

This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)

Dr. Reddy's appoints Sunil Gavaskar as the brand ambassador for its #TensionMatLo campaign

The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle

AiMeD expresses dismay over FICCI’s ‘Un-Make in India’ drive

Unfortunate to see PM’s ‘Make in India’ dream being bulldozed

Lupin Digital Health and American College of Cardiology collaborate for in-home cardiovascular care in India

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics

OMRON Healthcare to launch operations in March 2025 at Origins by Mahindra in Chennai

The OMRON Healthcare factory will be built over 6.02 acres and will be manufacturing blood pressure monitors and supplying them mainly to the domestic market.